-
Patient Related Outcome Measures
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Modified Severity of Dyspepsia Assessment pain scale: a new tool for measuring upper abdominal pain in osteoarthritis patients taking NSAIDs
Original Research
(4496) Total Article Views
Authors: Welle J, Fort J, Crawley J, Cryer B, Dickerhoof R, Turner MP, Miller KL
Published Date June 2011 Volume 2011:2 Pages 135 - 143
DOI: http://dx.doi.org/10.2147/PROM.S18077
Jennifer Welle1, John Fort2, Joseph Crawley3, Byron Cryer4, Rene Dickerhoof1, Michelle P Turner1, Kimberly L Miller11ICON Clinical Research, The Embarcadero, San Francisco, CA, USA; 2POZEN Inc, Raleigh Road, Chapel Hill, NC, USA; 3AstraZeneca LP, Concord Pike, Wilmington, DE, USA; 4UT Southwestern Medical Center, Harry Hines Boulevard, Dallas, TX, USA
Background: This study evaluated the electronically administered modified Severity of Dyspepsia Assessment (mSODA) pain scale, a six-item measure of upper abdominal pain intensity, for daily use in osteoarthritis patients taking nonsteroidal anti-inflammatory drugs.
Methods: Once the mSODA pain scale was isolated, cognitive debriefing interviews (n = 30) were used to examine its appropriateness in the target population. Following administration of the instrument in two Phase III pivotal trials, the data were analyzed to examine reliability, validity, responsiveness, and the minimal important difference.
Results: Using a subset of trial data (n = 90 patients), the mSODA pain scale proved to be a unidimensional, highly internally consistent instrument (α = 0.93) with good test-retest reliability (intraclass correlation coefficient 0.77). Construct validity was established via moderate correlations with other similar patient-reported outcomes. Additionally, known-groups validity demonstrated that the mSODA pain scale could distinguish between subjects who did and did not report gastrointestinal symptoms and antacid use (both P values ≤ 0.05). The mSODA pain scale was also responsive to change in heartburn at weeks 6 and 12 (Guyatt's statistic = 1.7 and 2.6, respectively), and the minimal important difference obtained via ½ SD was 5.7 (range 2–47).
Conclusion: This research suggests that the mSODA pain scale is both feasible and valid for assessing dyspepsia in patients taking nonsteroidal anti-inflammatory drugs for relief of symptoms of osteoarthritis.
Keywords: mSODA pain scale, questionnaire, antacid, patients, heartburn
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Health literacy and health seeking behavior among older men in a middle-income nation
- Prolonged rupture of membranes in term infants: should all babies be screened?
- Increasing access to quality health care for the poor: Community perceptions on quality care in Uganda
- Narcissistic rage: The Achilles’ heel of the patient with chronic physical illness